How to access Fabhalta from Oman, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Omani patient with paroxysmal nocturnal hemoglobinuria (PNH) may be evaluated by their treating haematologist for Fabhalta (iptacopan). Fabhalta is FDA-approved in the United States and manufactured by Novartis. It is the first oral monotherapy for PNH and a first-in-class factor B inhibitor, acting on the alternative complement pathway. Fabhalta is rarely locally registered outside the US and EU, and for Omani patients the named-patient import pathway via Oman Ministry of Public Health (MoPH) is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Fabhalta is administered as an oral capsule twice daily. It targets factor B in the alternative complement pathway, addressing both intravascular and extravascular haemolysis. Like other complement pathway inhibitors, it carries a US class-level warning about encapsulated-organism infections; vaccination (meningococcus, pneumococcus, Hib) is a gating step before therapy. Your treating haematologist confirms PNH diagnosis (flow cytometry), prior therapy history, vaccination completion, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Fabhalta legally importable into Oman?
Yes, through Oman Ministry of Public Health (MoPH) Pharmacy & Drug Control Department named-patient framework. The pathway allows an Oman-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For oral complement-pathway inhibitors, the named-patient route is the standard mechanism in Omani tertiary haematology, Fabhalta is not yet on a local formulary.
How the pathway works, step by step
- Consultation with your treating haematologist. PNH flow cytometry confirmation, prior therapy history, and clinical rationale.
- Pre-treatment vaccination. Meningococcal, pneumococcal, and Hib vaccinations per labeling.
- MoPH named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Fabhalta is an oral capsule with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming PNH, diagnostic evidence (flow cytometry), prior therapies, and Fabhalta as the indicated treatment
- Verification of their Oman medical licence
- Patient identifier
- Vaccination documentation
- Planned twice-daily oral regimen and monitoring cadence
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for complement-pathway inhibitors.
Costs and timing
Fabhalta's US cash-pay drug-only reference price for a 30-day supply sits in a broad indicative range of roughly USD 38,000-45,000. International logistics, MoPH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete application is submitted, plus vaccination lead time. Refills ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Mechanism, approval status, and treatment course
Fabhalta (iptacopan) is a oral, first-in-class proximal complement inhibitor that selectively binds factor B and blocks alternative-complement-pathway activation upstream of C3 cleavage, controlling both intravascular and extravascular hemolysis in PNH. FDA approval: 2023. EMA approval: 2024. The labelled indication is the paroxysmal nocturnal hemoglobinuria (PNH) in adults, and an expanded indication for C3 glomerulopathy and IgA nephropathy under accelerated approval. Fabhalta is supplied through the US specialty distribution channel only; Reserve Meds sources from a US-licensed authorised wholesaler under Drug Supply Chain Security Act (DSCSA) chain-of-custody and ships under the documentation framework DGPADC reviewers expect.
Dosing. Oral 200 mg twice daily. Taken with or without food. May be used as monotherapy or, with appropriate gradual cross-titration, as a switch from C5 inhibitors (eculizumab or ravulizumab) in PNH patients with residual extravascular hemolysis. The Omani treating physician documents the planned dose, the titration interval, and the response endpoint in the DGPADC application package.
Tertiary referral landscape in Oman
Fabhalta cases in Oman are most commonly initiated and followed at tertiary referral centres with subspecialty expertise in the indication. These include Sultan Qaboos University Hospital, Royal Hospital Muscat, and Khoula Hospital. The treating physician of record (the Omani-licensed neurologist, haematologist, or relevant subspecialist) holds clinical responsibility for the case; Reserve Meds does not interpose between the patient and the prescriber. DGPADC pathway submissions are filed by the treating physician or the hospital pharmacy department, and Reserve Meds supplies the regulatory documentation package that DGPADC reviewers expect.
Where the patient is followed at a non-tertiary clinic, the patient is typically referred for the Fabhalta initiation visit to one of the centres above and then returns to local follow-up with monthly or quarterly tertiary review, depending on the clinical picture. Reserve Meds coordinates the refill cadence so that the next shipment is in country at least 7 days before the patient's current supply ends.
Monitoring and continuity of care
The Omani treating physician follows a standard monitoring schedule once Fabhalta is initiated:
- Hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and absolute reticulocyte count at baseline, 2 weeks, 4 weeks, 12 weeks, then quarterly to document hematologic response
- Complete blood count and renal function monthly in the first 6 months, then quarterly
- PNH clone size (granulocyte and red-cell flow cytometry) at baseline and annually; clone size does not direct dose but informs prognosis and disease activity
Reserve Meds is not involved in the clinical monitoring itself, but supplies refill cadence reminders to the patient and the treating physician so that the next-month supply is delivered in advance of the patient's next scheduled clinic visit. The first refill is shipped at week 3 of the initial cycle so that any titration adjustment from the 4-week visit can be reflected in the dose supplied for cycle 2.
Concomitant medications and safety considerations
Before Fabhalta is initiated, the Omani treating physician reconciles every concomitant prescription, over-the-counter, and herbal medicine the patient is taking. Key safety points the physician documents in the DGPADC package:
- Encapsulated-organism infection risk is the principal safety concern: Neisseria meningitidis (serogroups A, C, W, Y, B), Streptococcus pneumoniae, and Haemophilus influenzae type b. Vaccination at least 2 weeks before initiation is mandatory, and prophylactic antibiotics are required for patients who must start before adequate vaccination coverage
- Patients carry a Fabhalta Patient Safety Card and are counselled to seek immediate medical attention for fever, headache with neck stiffness, or photophobia
- Hyperlipidemia (LDL-cholesterol elevation) is reported in approximately 25 percent of patients; lipid panel at 12 weeks and annually with statin initiation per standard cardiovascular risk algorithms
The patient is given a written counselling document in the language of care identifying which symptoms warrant immediate clinical contact and which can wait for the next scheduled visit. Reserve Meds supplies a generic counselling-document template that the treating physician adapts to the patient's case.
Funding considerations in Oman
Fabhalta is supplied on a cash-pay basis. Some Omani private medical insurers consider named-patient imports of FDA-labelled medicines on a case-by-case basis, particularly when the insurer's medical director can review the clinical rationale letter and the DGPADC authorisation. Reserve Meds supplies the documentation package the insurer requires for review but does not adjudicate or process claims directly.
For self-pay patients, Reserve Meds issues a transparent quote at intake covering the drug-only band, international logistics, DGPADC documentation handling, and concierge case coordination. The quote is fixed for the duration of the initial 90-day cycle and re-issued for each subsequent cycle if the dose changes. Patients are encouraged to ask their Omani treating physician about manufacturer patient-assistance pathways where available, although most US manufacturer assistance programs are restricted to US residents.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Fabhalta specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoPH review.
- Logistics. Tamper-evident, internationally tracked shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.
Frequently asked
Is this legal in Oman? Yes, when executed through the MoPH named-patient framework with appropriate documentation.
Why Fabhalta rather than a C5 or C3 inhibitor? Fabhalta's oral route is a major quality-of-life factor, no infusions or subcutaneous injections. Efficacy data support its use as monotherapy in PNH, including in patients with persistent anaemia on C5 inhibition. Your haematologist will decide.
What about the vaccination requirement? It is load-bearing. Encapsulated-organism vaccination per labeling is completed before therapy starts.
Will private insurance cover this? Cash-pay is the default. Some Omani insurers reimburse named-patient imports for ultra-rare-disease therapies on escalated review; we supply documentation for your submission but do not process insurance claims directly.
How does Fabhalta differ from eculizumab and ravulizumab? Eculizumab and ravulizumab are intravenous C5 inhibitors that block terminal complement and prevent intravascular hemolysis but leave residual extravascular hemolysis via C3-fragment opsonization. Fabhalta is oral, twice daily, and blocks upstream at factor B, controlling both intravascular and extravascular hemolysis. Many patients on C5 inhibitors with persistent anemia or transfusion dependence experience hemoglobin improvement after switching.
Can the patient skip the meningococcal vaccine if they had it before for eculizumab? No. Vaccination records are reviewed and boosters administered per CDC and local immunisation schedule. The Fabhalta REMS-equivalent risk-management plan requires documented current vaccination coverage before the first dose.
Is Fabhalta a curative therapy for PNH? No. PNH is caused by an acquired PIGA mutation in hematopoietic stem cells; only allogeneic stem cell transplant is potentially curative. Fabhalta controls hemolysis and anemia while the patient remains on therapy. Discontinuation typically returns hemolysis to baseline within 1 to 2 weeks.
How does the patient travel internationally with Fabhalta? Fabhalta is supplied as an oral capsule with no cold-chain requirement. The patient carries the Patient Safety Card, the prescribing letter, and a 30-day supply minimum in hand luggage. Reserve Meds coordinates monthly refill timing to ensure continuity across travel.
Next step
For Fabhalta coordination in Oman, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.